Navigation Links
USC and second sight announce European clinical trial for Argus II retinal implant

Boston, MA, February 15, 2008 USC and Second Sight Medical Products Inc, leading developers of retinal prostheses for treating blindness, announced today that they have completed enrollment of the first phase of a U.S .FDA approved clinical study of the Argus II Retinal Prosthesis System. They also announced that enrollment at key European sites is underway as studies continue in Mexico.

We are pleased that Second Sight, along with our fantastic clinical partners, was able to fully enroll the US trial in a timely manner, said Robert Greenberg, MD, PhD, President and CEO of Second Sight, and a leader in the field of retinal prostheses for more than 15 years.

Although it is too early to comment on the clinical data, each device continues to function as expected, and all participants are using their systems at home daily.

The Argus II is the second generation of an electronic retinal implant designed for the treatment of blindness due to Retinitis Pigmentosa (RP), a group of inherited eye diseases that affect the retina. The Argus II implant consists of an array of 60 electrodes that are attached to the retina. These electrodes conduct information acquired from an external camera to the retina to provide a rudimentary form of sight to implanted subjects.

The development of this technology was largely supported by the National Eye Institute (NEI) of the National Institutes of Health (NIH), and the Department of Energys Office of Science (DOE) Artificial Retina Project, which is helping to advance the implants design and construction. The unique resources and expertise at DOE national laboratoriesparticularly in engineering, microfabrication, material science, and microelectronic technologiesare enabling the development of much smaller, higher resolution devices.

Ten subjects were recruited for the Phase I trial at four leading ophthalmic centers throughout the US, including the Doheny Eye Institute at the University of Southern California (USC), Wilmer Eye Institute at Johns Hopkins University (Baltimore), the University of California at San Francisco, and the Retina Foundation of the Southwest (Dallas). Second Sight will be seeking expansion of the U.S. trial to include other trial sites located in New York (Columbia University Medical Center and Lighthouse International), Philadelphia (Scheie Eye Institute and Wills Eye Hospital) and Atlanta (Emory University and Atlanta V.A. Rehab R&D Center). This three-year Investigational Device Exemption (IDE) trial is the only long-term study of a retinal prosthesis currently being conducted anywhere in the world.

Internationally, the Argus II study began in Mexico in the fall of 2006 at Centro de Retina Medica y Quirurgica, SC, Centro Medico Puerta de Hierro, CUCS, Universidad de Guadalajara (Guadalajara, Jal.). More recently, enrollment has just begun at two European sites, including Service dOphtalmologie, Hpital Cantonal, Universitaire de Genve (Geneva, Switzerland) and Le Centre Hospitalier National DOphtalmologie Des Quinze-Vingts (Paris, France). A third study site at Moorfields Eye Hospital in London has recently received government approval and is expected to begin enrollment shortly.

The pioneering efforts of the individuals that participate in this clinical trial will lead to advances for the many people in the world afflicted with blindness, said Mark Humayun, MD, PhD, Professor of Ophthalmology, Biomedical Engineering, and Cellular and Neurobiology at the Doheny Eye Institute, Keck School of Medicine of USC, and Viterbi School of Engineering and the first physician to perform an Argus II implantation procedure in the US.

Dr. Humayun was the vitreo-retinal surgeon for the first generation 16-electrode (Argus 16), which he implanted in six RP subjects between 2002 and 2004. The study demonstrated the ability of participants to detect when lights are on or off, describe an objects motion, count discrete items, as well as locate and differentiate basic objects in an environment.

"We are excited about the progress being made in the development of this artificial retina technology," says Stephen Rose, PhD, Chief Research Officer, Foundation Fighting Blindness (FFB).

"FFB supported early preclinical studies of this technology, because of its great potential for giving vision to people with the most advanced retinal disease and we are pleased to have helped advance the prosthesis into critical clinical trials."


Contact: Jon Weiner
University of Southern California

Related biology technology :

1. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
2. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
3. Escalon(R) Reports Second Quarter Fiscal 2008 Results
4. Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
5. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
6. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
7. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
8. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008
9. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
10. Nutrition 21 to Report Second Quarter Fiscal 2008 Financial Results Monday, February 11, 2008
11. Neurobiological Technologies Sets Date for Second Quarter Financial Results
Post Your Comments:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... bring innovative medical technologies, services and solutions to the healthcare market. The company's ... of various distribution, manufacturing, sales and marketing strategies that are necessary to help ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
Breaking Biology Technology:
(Date:6/22/2016)...  The American College of Medical Genetics and Genomics was ... as one of the fastest-growing trade shows during the Fastest ... in Las Vegas . ... in each of the following categories: net square feet of ... attendees. The 2015 ACMG Annual Meeting was ranked 23 out ...
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/3/2016)... Das DOTM (Department ... hat ein 44 Millionen $-Projekt ... einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an Decatur ... Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale Anbieter ... aber Decatur wurde als konformste und innovativste ...
Breaking Biology News(10 mins):